Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Nov;55(11):111827.
doi: 10.1016/j.injury.2024.111827. Epub 2024 Aug 20.

Mortality, perioperative complications and surgical timelines in hip fracture patients: Comparison of the Spanish with the non-Spanish Cohort of the HIP ATTACK-1 trial

Collaborators, Affiliations
Randomized Controlled Trial

Mortality, perioperative complications and surgical timelines in hip fracture patients: Comparison of the Spanish with the non-Spanish Cohort of the HIP ATTACK-1 trial

Ernesto Guerra-Farfan et al. Injury. 2024 Nov.

Abstract

Background: Hip fractures carry a substantial risk of complications and death. This study aimed to report the 90-day incidence of mortality, major perioperative complications and in-hospital timelines after a hip fracture in the Spanish HIP ATTACK-1 trial cohort, comparing with the non-Spanish cohort.

Methods: Prospective cohort study of Spanish patients nested in the HIP ATTACK-1 trial. The HIP ATTACK-1 was an international, randomized, controlled trial (17 countries, 69 hospitals, 7 in Spain, highest recruiting country). Patients were randomized to either accelerated surgery (goal of surgery within 6 h of diagnosis) or standard care. Participants were ≥45 years of age who presented with a low-energy hip fracture requiring surgery.

Results: Among 534 patients in the Spanish cohort, 69 (12.9 %) patients died at 90 days follow-up, compared to 225 (9.2 %) in the non-Spanish cohort (p = 0.009), mostly due to higher nonvascular related mortality. A composite of major postoperative complication occurred in 126 patients (23.6 %). The most common perioperative complications were myocardial injury (189 patients, 35.4 %), infection with no sepsis (86 patients, 16.1 %) and perioperative delirium (84 patients, 15.7 %); all these complication rates in Spain were significantly higher than the non-Spanish patients (29.2 % p = 0.005; 11.9 % p = 0.008 and 9.2 % p < 0.0001, respectively). Spanish cohort patients were older and had more comorbidities than the non-Spanish cohort, evidencing their greater frailty at baseline. Among Spanish patients, the median time from hip fracture diagnosis to surgery was 30.0 h (IQR 21.1-53.9) in the standard-care group, with 68.8 % of patients receiving surgery within 48 h of diagnosis. This median time was lower in the non-Spanish cohort (22.8 h, IQR 9.5-37.0), where 82.1 % of patients were operated within 48 h.

Conclusions: In the HIP ATTACK-1 trial, 1 in 8 patients died 90 days after a hip fracture in Spain. The most common complication after a hip fracture was myocardial injury, followed by infection and delirium. Spanish patients had worse outcomes than non-Spanish patients. Research needs to focus on new interventions such as accelerated surgery and perioperative troponin measurement with the appropriate investment of resources, to prevent and identify early these complications with a goal of improving mortality for this high-risk population.

Level of evidence: II.

Keywords: Accelerated; Hip fracture; Medical outcomes; Mortality; Perioperative complications; Surgical procedure; Surgical timelines.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr. Ernesto Guerra-Farfán and Dr. PJ Devereaux received research grants from Smith & Nephew for this investigator-initiated trial. Based on study questions Dr. PJ Devereaux originated and grants he has written, he has received grants from Abbott Diagnostics, Roche Diagnostics, and Siemens. Dr. Flavia K Borges received investigator-initiated research grants from Roche diagnostics and SIEMENS. Mohit Bhandari (g), Yaiza Garcia-Sanchez (h), Jorge H. Nuñez (c,i), Jaume Mestre-Torres (j), Jordi Tomas-Hernandez (a), Jordi Teixidor-Serra (a), Mariano Balaguer-Castro (k), Pablo Castillón (i), Alfred Dealbert (l), Julio De Caso Rodriguez (m), Hector J. Aguado (n), Enrique Guerado (o), Ekaterine Popova(m), Ana Claudia Tonelli (p), Kumar Balasubramanian (e), Jessica Vincent (e), Valerie Harvey (e), Etri Kocaqi (q) and Gerard Slobogean (r s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Publication types